Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study

Basit Öğe Kaydı
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorÖz, Büge
dc.contributor.authorBilici, Ahmet
dc.contributor.authorGürsoy, Pınar
dc.contributor.authorGöker, Erdem
dc.contributor.authorSezer, Ahmet
dc.contributor.authorÖzet, Ahmet
dc.contributor.authorDemirci, Umut
dc.contributor.authorBozkurtlar, Emine
dc.contributor.authorÖzbudak, İrem Hicran
dc.contributor.authorNart, Deniz
dc.contributor.authorCanpolat, Tuğba
dc.contributor.authorAkyürek, Nalan
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2023-03-15T06:30:24Z
dc.date.available2023-03-15T06:30:24Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. We aimed to study the impact of ALK fusion variants on the survival of first-line crizotinib-treated NSCLC patients. Methods: 101 locally advanced or metastatic ALK positive NSCLC patients treated with first-line crizotinib between January 2013 and December 2019 were retrospectively evaluated. We studied ALK fusion variants in 38 of those patients with adequate tumor tissue with reverse transcription polymerase chain reaction (RT PCR). Patients having ALK fusion variant 1 (v1) and non-variant 1 (non-v1) were compared for survival and response to crizotinib. Results: Median age was 52.5 years (range 35-74), and 22 of 38 patients were male (57.9%). EML-4 ALK v1 was seen in 26 patients (68.4%) and 12 were non-v1 (variant 3a/b in 6, and non-EML-4 ALK variants in 6 patients). Objective response rate was 60.5% in all patients, whereas it was 61.5% in v1 and 58.3% in non-v1 group. Median progression-free survival (PFS) and overall survival (OS) were similar. Median PFS was 13.1 months in v1, and 12.4 months in non-v1 (p=0.232). Median OS was 23.2 months in v1, and 19.4 months non-v1 (p=0.493). Conclusion: ALK v1 and non-v1 patients had the same OS and PFS after first-line crizotinib treatment, however there was a trend for v1 group for better OS.
dc.description.sponsorshipTurkish Oncology Groupen_US
dc.identifier.citationTatlı, A. M., Yumuk, P. F., Öz, B., Bilici, A., Gürsoy, P., Göker, E. ... Kılıçkap, S. (2021). Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study. Journal of B.U.ON., 26(6), 2457-2464.
dc.identifier.endpage2464
dc.identifier.issn1107-0625
dc.identifier.issue6
dc.identifier.scopus2-s2.0-85123519923
dc.identifier.scopusqualityN/A
dc.identifier.startpage2457
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10619
dc.identifier.volume26
dc.indekslendigikaynakScopus
dc.institutionauthorBilici, Ahmet
dc.language.isoen
dc.publisherZerbinis Publications
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectALK Inhibitor
dc.subjectCrizotinib
dc.subjectEML4-ALK Fusions
dc.subjectNon-Small Cell Lung Cancer
dc.titleComparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu